SNCA and Parkinson disease: Targeted preclinical testing of pharmacological treatment candidates is proposed to address individual derangements of PD pathology (e.g., iron and calcium overload, dysfunctions of the MT, organelles, mutant β-glucocerebrosidase and α-synuclein, chronic neuroinflammation, and disrupted autophagy) [309,310,311,312,313,314,315,316].